Stories about Medikament
- 3One documentmore
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
moreTechnische Universität München
Minimizing antibiotics usage: “The key starting point is animal health”
TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Interview with Prof. Julia Steinhoff-Wagner on antibiotic resistance “The key starting point is animal health” - New research project at TUM addresses the minimization of antibiotics in poultry farming - Healthy animals are the most important precondition for reducing the administration of antibiotics - Transfer of ...
moreDeepMB: A Deep Learning Framework For High-Quality Optoacoustic Imaging in Real-Time
moreGerresheimer at CPHI: focus on high-value solutions and sustainability
Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...
more
Takeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
morePress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
more- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore Technische Universität München
4D printing for nerve stimulation: Self-folding electrodes stimulate fine nerves
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Self-folding electrodes stimulate fine nerves 4D printing for nerve stimulation - Researchers have produced very fine, flexible electrodes - Upon contact with tissue moisture, the electrodes wrap themselves around thin nerves - Nerve stimulation and recording with the foldable electrodes has already been demonstrated in ...
moreThe Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
moreBirth weight and head circumference predict IQ and motor performance at 4 years of age
more
Fraunhofer-Institut für Produktionstechnologie IPT
Joint expertise from industry and research: New regulations standardize optical coherence tomography
moreTechnische Universität München
Genetically encoded nano-barcodes
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
more- 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories
Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...
moreThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
moreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmore
Blood Donation Day at R-Biopharm: Employees Help Save Lives
moreBreakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded
moreCO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg
Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...
moreTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
moreTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
moreFlu tests from R-Biopharm also detect new virus variants
more
Technische Universität München
Tumors: forecasting the risks of brain surgery
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 18198 - email: presse@tum.de - web: www.tum.de This text on the web: http://go.tum.de/619311 Pictures: http://go.tum.de/010709 - http://go.tum.de/959985 - http://go.tum.de/098359 - http://go.tum.de/754050 - http://go.tum.de/109729 Accurately predicting possible post-surgical effects on speech Tumors: forecasting the risks of brain surgery ...
moreStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
moreTechnische Universität München
Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid aggregates
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22779 - email: presse@tum.de - web: www.tum.de Image download: https://mediatum.ub.tum.de/652209?show_id=1691364 NEWS RELEASE Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid ...
moreVectorBuilder Raised $57 Million for Gene Delivery R&D
moreVectorBuilder raised $57 million for gene delivery R&D
moreMetrics in Balance und DNA Talks schließen sich zusammen und betreten den europäischen Lifestyle-Markt unter einem neuen Namen: LifeTalks
more